PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(12): 1212-1220
DOI: 10.1055/a-1128-0168
GebFra Science
Review/Übersicht

Status of Sentinel Lymph Node Biopsy in Vulvar and Cervical Cancer

Artikel in mehreren Sprachen: English | deutsch
Julia Waldschmidt
Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany
,
Lisa Jung
Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany
,
Ingolf Juhasz-Böss
Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Assessment of lymphatic metastasis is an essential component of solid tumour staging. Sentinel lymph node (SLN) biopsy is a minimally invasive procedure that allows regional lymph node involvement by tumour to be estimated by selectively examining the sentinel lymph node while minimising the morbidity of systematic lymph node dissection. Within the group of genital cancers, the diagnostic value of SLN biopsy is rated differently. For selected patients with early-stage vulvar cancer (unifocal primary tumour < 4 cm, clinically negative inguinal lymph nodes) the SLN technique is already an established procedure in the guidelines of the German Society for Gynaecology and Obstetrics (DGGG)/German Cancer Society (DKG) and the recommendations of the European Society of Gynaecological Oncology (ESGO). For cervical cancer, SLN biopsy has not yet been sufficiently standardised but can be considered for patients without risk factors with a primary tumour size < 2 cm. The SLN is identified by combined use of radioactive 99mtechnetium nanocolloid and patent blue. The use of indocyanine green offers an alternative for SLN identification with few side effects. Recent studies aim to increase the diagnostic reliability of intraoperative frozen section analysis as this continues to show limited sensitivity in both vulvar and cervical cancer. The rate of detection of micrometastases can be increased by additional ultrastaging, the prognostic significance of which for both diseases is still unclear. The prognostic value of SLN biopsy compared with systematic lymph node dissection is being investigated in current studies (GROINSS-V-II for vulvar cancer and SENTIX-, SENTICOL-3 for cervical cancer). For this review article, a guideline-based literature search was performed in the National Library of Medicine (PubMed/MEDLINE) database with a particular focus on recent cohort studies and conference contributions.

Key words

vulvar cancer - cervical cancer - sentinel lymph node - ultrastaging - micrometastases


Publikationsverlauf

Eingereicht: 27. Juli 2020

Angenommen nach Revision: 26. Oktober 2020

Artikel online veröffentlicht:
03. Dezember 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Morton DL, Wen DR, Wong JH. et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399
    CrossrefPubMedGoogle Scholar
  • 2 Cody HS. Sentinel lymph node mapping in breast cancer. Breast Cancer 1999; 6: 13-22
    CrossrefPubMedGoogle Scholar
  • 3 Mocellin S, Hoon DSB, Pilati P. et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25: 1588-1595
    CrossrefPubMedGoogle Scholar
  • 4 AWMF, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG). Langfassung der Leitlinie „Vulvakarzinom und seine Vorstufen, Diagnostik und Therapie“. 01.11.2015 Accessed September 27, 2020 at: https://www.awmf.org/leitlinien/detail/ll/015-059.html
    Google Scholar
  • 5 AWMF; Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG), Deutsche Krebsgesellschaft (DKG). Langfassung der Leitlinie „Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom“. 15.10.2014 Accessed September 27, 2020 at: https://www.awmf.org/leitlinien/detail/ll/032-033OL.html
    Google Scholar
  • 6 AWMF; Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG), Deutsche Krebsgesellschaft (DKG). Langfassung der Leitlinie „Diagnostik, Therapie und Nachsorge der Patientin mit Endometriumkarzinom“. 30.04.2018 Accessed September 27, 2020 at: https://www.awmf.org/leitlinien/detail/ll/032-034OL.html
    Google Scholar
  • 7 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30
    CrossrefPubMedGoogle Scholar
  • 8 Robert Koch-Institut, Zentrum der Krebsregisterdaten. Vulva: Übersicht über die wichtigsten epidemiologischen Maßzahlen für Deutschland, ICD-10 C51. Berlin: Robert Koch-Institut; 2016. Accessed September 27, 2020 at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/kid_2019_c51_vulva.pdf?__blob=publicationFile
    Google Scholar
  • 9 Mahner S, Jueckstock J, Hilpert F. et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 2015; 107: dju426
    CrossrefPubMedGoogle Scholar
  • 10 Hyde SE, Valmadre S, Hacker NF. et al. Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy. Int J Gynecol Cancer 2007; 17: 154-158
    CrossrefPubMedGoogle Scholar
  • 11 Levenback C, Burke TW, Gershenson DM. et al. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994; 84: 163-167
    PubMedGoogle Scholar
  • 12 Van der Zee AGJ, Oonk MH, De Hullu JA. et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008; 26: 884-889
    CrossrefPubMedGoogle Scholar
  • 13 European Society of Gynecological Oncology (ESGO). ESGO Guidelines for the Management of Vulvar Cancer. 2017 Accessed September 27, 2020 at: https://guidelines.esgo.org/vulvar-cancer/guidelines/recommendations
    Google Scholar
  • 14 Hassanzade M, Attaran M, Treglia G. et al. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 130: 237-245
    CrossrefPubMedGoogle Scholar
  • 15 Hampl M, Hantschmann P, Michels W. et al. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol 2008; 111: 282-288
    CrossrefPubMedGoogle Scholar
  • 16 Soergel P, Hertel H, Nacke AK. et al. Sentinel Lymphadenectomy in Vulvar Cancer Using Near-Infrared Fluorescence From Indocyanine Green Compared With Technetium 99m Nanocolloid. Int J Gynecol Cancer 2017; 27: 805-812
    CrossrefPubMedGoogle Scholar
  • 17 Papadia A, Gasparri ML, Buda A. et al. Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue. J Cancer Res Clin Oncol 2017; 143: 2039-2048
    CrossrefPubMedGoogle Scholar
  • 18 Hackethal A, Hirschburger M, Eicker SO. et al. Role of Indocyanine Green in Fluorescence Imaging with Near-Infrared Light to Identify Sentinel Lymph Nodes, Lymphatic Vessels and Pathways Prior to Surgery – A Critical Evaluation of Options. Geburtshilfe Frauenheilkd 2018; 78: 54-62
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Oonk MH, van Hemel BM, Hollema H. et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol 2010; 11: 646-652
    CrossrefPubMedGoogle Scholar
  • 20 Vidal-Sicart S, Puig-Tintoré LM, Lejárcegui JA. et al. Validation and application of the sentinel lymph node concept in malignant vulvar tumours. Eur J Nucl Med Mol Imaging 2007; 34: 384-391
    CrossrefPubMedGoogle Scholar
  • 21 Achimas-Cadariu P, Harter P, Fisseler-Eckhoff A. et al. Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva. Acta Obstet Gynecol Scand 2009; 88: 1209-1214
    CrossrefPubMedGoogle Scholar
  • 22 Devaja O, Mehra G, Coutts M. et al. A prospective study of sentinel lymph node detection in vulval carcinoma: is it time for a change in clinical practice?. Int J Gynecol Cancer 2011; 21: 559-564
    CrossrefPubMedGoogle Scholar
  • 23 Levenback CF, Ali S, Coleman RL. et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol 2012; 30: 3786-3791
    CrossrefPubMedGoogle Scholar
  • 24 Euscher ED, Malpica A. Gynaecological malignancies and sentinel lymph node mapping: an update. Histopathology 2020; 76: 139-150
    CrossrefPubMedGoogle Scholar
  • 25 Covens A, Vella ET, Kennedy EB. et al. Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations. Gynecol Oncol 2015; 137: 351-361
    CrossrefPubMedGoogle Scholar
  • 26 Moore RG, Granai CO, Gajewski W. et al. Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecol Oncol 2003; 91: 378-382
    CrossrefPubMedGoogle Scholar
  • 27 Meads C, Sutton AJ, Rosenthal AN. et al. Sentinel lymph node biopsy in vulval cancer: systematic review and meta-analysis. Br J Cancer 2014; 110: 2837-2846
    CrossrefPubMedGoogle Scholar
  • 28 Reade CJ, Jimenez W, OʼReilly D. et al. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. J Obstet Gynaecol Can 2012; 34: 1053-1065
    CrossrefPubMedGoogle Scholar
  • 29 Oonk MHM, van Os MA, de Bock GH. et al. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol 2009; 113: 301-305
    CrossrefPubMedGoogle Scholar
  • 30 Brammen L, Staudenherz A, Polterauer S. et al. Sentinel lymph node detection in vulvar cancer patients: a 20 years analysis. Hell J Nucl Med 2014; 17: 184-189
    CrossrefPubMedGoogle Scholar
  • 31 Hefler LA, Grimm C, Six L. et al. Inguinal sentinel lymph node dissection vs. complete inguinal lymph node dissection in patients with vulvar cancer. Anticancer Res 2008; 28: 515-517
    PubMedGoogle Scholar
  • 32 Coleman RL, Ali S, Levenback CF. et al. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol 2013; 128: 155-159
    CrossrefPubMedGoogle Scholar
  • 33 Te Grootenhuis NC, van der Zee AGJ, van Doorn HC. et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol 2016; 140: 8-14
    CrossrefPubMedGoogle Scholar
  • 34 Oonk M, Slomovitz B, Baldwin P. et al. Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II. Int J Gynecol Cancer 2019; 29: A14
    PubMedGoogle Scholar
  • 35 Lindell G, Jonsson C, Ehrsson RJ. et al. Evaluation of preoperative lymphoscintigraphy and sentinel node procedure in vulvar cancer. Eur J Obstet Gynecol Reprod Biol 2010; 152: 91-95
    CrossrefPubMedGoogle Scholar
  • 36 Louis-Sylvestre C, Evangelista E, Leonard F. et al. Sentinel node localization should be interpreted with caution in midline vulvar cancer. Gynecol Oncol 2005; 97: 151-154
    CrossrefPubMedGoogle Scholar
  • 37 Woelber L, Eulenburg C, Grimm D. et al. The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. Ann Surg Oncol 2016; 23: 2508-2514
    CrossrefPubMedGoogle Scholar
  • 38 Robert Koch-Institut. Startseite Zentrum für Krebsregisterdaten. 2016 Accessed July 27, 2020 at: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Gebaermutterhalskrebs/gebaermutterhalskrebs_node.html
    Google Scholar
  • 39 Robert Koch-Institut. Startseite Zentrum für Krebsregisterdaten. 2013 . Accessed July 27, 2020 at: http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/krebs_in_deutschland_2013.pdf;jsessionid=46DBFE3D158B3FAC7325A798CA3A803F.2_cid372?__blob=publicationFile
    Google Scholar
  • 40 Euscher ED, Malpica A, Atkinson EN. et al. Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. Am J Surg Pathol 2008; 32: 1336-1343
    CrossrefPubMedGoogle Scholar
  • 41 Koh W-J, Abu-Rustum NR, Bean S. et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17: 64-84
    CrossrefPubMedGoogle Scholar
  • 42 European Society of Gynecological Oncology (ESGO). ESGO Guidelines for the Management of Cervical Cancer. 2017 Accessed September 27, 2020 at: https://guidelines.esgo.org/cervical-cancer/guidelines/recommendations
    Google Scholar
  • 43 Darin MC, Gómez-Hidalgo NR, Westin SN. et al. Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. J Minim Invasive Gynecol 2016; 23: 186-193
    CrossrefPubMedGoogle Scholar
  • 44 Buda A, Crivellaro C, Elisei F. et al. Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer (99m)Tc and/or Blue Dye. Ann Surg Oncol 2016; 23: 2183-2191
    CrossrefPubMedGoogle Scholar
  • 45 Buda A, Papadia A, Zapardiel I. et al. From Conventional Radiotracer Tc-99(m) with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach. Ann Surg Oncol 2016; 23: 2959-2965
    CrossrefPubMedGoogle Scholar
  • 46 Roy M, Bouchard-Fortier G, Popa I. et al. Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol 2011; 122: 269-274
    CrossrefPubMedGoogle Scholar
  • 47 Bats A-S, Buénerd A, Querleu D. et al. Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study. Gynecol Oncol 2011; 123: 230-235
    CrossrefPubMedGoogle Scholar
  • 48 Balaya V, Guani B, Benoit L. et al. Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging. Gynecol Oncol 2020; 158: 576-583
    CrossrefPubMedGoogle Scholar
  • 49 Selman TJ, Mann C, Zamora J. et al. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ 2008; 178: 855-862
    CrossrefPubMedGoogle Scholar
  • 50 Niikura H, Tsuji K, Tokunaga H. et al. Sentinel node navigation surgery in cervical and endometrial cancer: a review. Jpn J Clin Oncol 2019; 49: 495-500
    CrossrefPubMedGoogle Scholar
  • 51 Gianoni M, Mathevet P, Uzan C. et al. Does the Sentinel Lymph Node Sampling Alone Improve Quality of Life in Early Cervical Cancer Management?. Front Surg 2020; 7: 31
    CrossrefPubMedGoogle Scholar
  • 52 Bats A-S, Mathevet P, Buenerd A. et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol 2013; 20: 413-422
    CrossrefPubMedGoogle Scholar
  • 53 Bats A-S, Frati A, Mathevet P. et al. Contribution of lymphoscintigraphy to intraoperative sentinel lymph node detection in early cervical cancer: Analysis of the prospective multicenter SENTICOL cohort. Gynecol Oncol 2015; 137: 264-269
    CrossrefPubMedGoogle Scholar
  • 54 Marnitz S, Köhler C, Bongardt S. et al. Topographic distribution of sentinel lymph nodes in patients with cervical cancer. Gynecol Oncol 2006; 103: 35-44
    CrossrefPubMedGoogle Scholar
  • 55 Lécuru F, Mathevet P, Querleu D. et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol 2011; 29: 1686-1691
    CrossrefPubMedGoogle Scholar
  • 56 Cibula D, Abu-Rustum NR, Dusek L. et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 2012; 127: 462-466
    CrossrefPubMedGoogle Scholar
  • 57 Salvo G, Ramirez PT, Levenback CF. et al. Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecol Oncol 2017; 145: 96-101
    CrossrefPubMedGoogle Scholar
  • 58 Altgassen C, Hertel H, Brandstädt A. et al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 2008; 26: 2943-2951
    Google Scholar
  • 59 Balaya V, Bresset A, Guani B. et al. Risk factors for failure of bilateral sentinel lymph node mapping in early-stage cervical cancer. Gynecol Oncol 2020; 156: 93-99
    CrossrefPubMedGoogle Scholar
  • 60 Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol 2019; 152: 202-207
    CrossrefPubMedGoogle Scholar
  • 61 Popa I, Plante M, Renaud M-C. et al. Negative sentinel lymph node accurately predicts negative status of pelvic lymph nodes in uterine cervix carcinoma. Gynecol Oncol 2006; 103: 649-653
    CrossrefPubMedGoogle Scholar
  • 62 Barranger E, Cortez A, Commo F. et al. Histopathological validation of the sentinel node concept in cervical cancer. Ann Oncol 2004; 15: 870-874
    CrossrefPubMedGoogle Scholar
  • 63 Okamoto S, Niikura H, Yoshinaga K. et al. Detection of micrometastases in cervical cancer with a system that evaluates both sentinel and nonsentinel lymph nodes. Int J Gynecol Cancer 2009; 19: 708-711
    CrossrefPubMedGoogle Scholar
  • 64 Cibula D, Zikan M, Slama J. et al. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. Gynecol Oncol 2016; 143: 83-86
    CrossrefPubMedGoogle Scholar
  • 65 Cibula D, Abu-Rustum NR, Dusek L. et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 2012; 124: 496-501
    CrossrefPubMedGoogle Scholar
  • 66 Colturato LF, Signorini Filho RC, Fernandes RCM. et al. Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. Int J Gynaecol Obstet 2016; 133: 69-75
    CrossrefPubMedGoogle Scholar
  • 67 Guani B, Dorez M, Magaud L. et al. Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial. Int J Gynecol Cancer 2019; 29: 447-452
    CrossrefPubMedGoogle Scholar
  • 68 Guani B, Balaya V, Magaud L. et al. The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials. Cancers (Basel) 2020; 12: 1061
    CrossrefPubMedGoogle Scholar
  • 69 Balaya V, Guani B, Magaud L. et al. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer. JCO 2020; 38: 6006-6006
    CrossrefPubMedGoogle Scholar